KRYS

As of 2026-10-26, KRYS scores 44out of 100 on QNTM’s five-factor quantitative model, a low conviction reading. The score blends momentum, quality, volume, value and sentiment, then adjusts for the current macro regime. KRYS trades at $313.66, 54% above the band ceiling.

KRYS scores 44 out of 100 on QNTM's five-factor model — a low-conviction reading — at 44 the factor profile is among the weaker names in the universe. Its strongest factor is quality at 58 (solid), where earnings quality and balance-sheet strength stand out, followed by value at 50. The weakest is sentiment at 20, where sentiment signals are working against it. Among Healthcare stocks it sits in the lower 27% of Healthcare names by composite.

On valuation, KRYS is priced near the top of its recent range — the rich end on the model's valuation read. The blended composite before the macro overlay was 45. Same-sector names the model rates nearby include HALO, VEEV, THC.

This is a descriptive factor read on KRYS, recomputed each trading day and shown with its reasoning — not a recommendation to buy, hold or sell. The score reflects where KRYS sits on the model's measures today, and can change as new data arrives.

FACTOR BREAKDOWN

VALUATION RANGE

QNTM’s descriptive fair-value band for KRYS runs $136.02–$203.20. Current price $313.66 sits 54% above the band ceiling. This is valuation context, not a price target.

OTHER HEALTHCARE NAMES

QNTM provides quantitative model outputs for informational and educational purposes only. It is not investment advice and QNTM is not a registered investment adviser. Scores are rankings, not buy/sell recommendations. Data as of 2026-10-26.